Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus

References

• Centers for Disease Control and PreventionDiabetesaccessed January 18 2006 Available at http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf
   Google Scholar
• WeberADipeptidyl peptidase IV inhibitors for the treatment of diabetesJ Med Chem2004474135414115293982
   PubMed Web of Science ®Google Scholar
• DooseopKWangLBeconiMEiermannGJFisherMHHeH(2R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetesJ Med Chem200548114115115634008
   PubMed Web of Science ®Google Scholar
• CreutzfeldtWThe [pre-] history of the incretin conceptRegul Pept2005128879115780427
   PubMed Web of Science ®Google Scholar
• McIntoshCDemuthHPospisilikJPedersonRDipeptidyl peptidase IV inhibitors: how do they work as new antidiabetic agents?Regul Pept200512815916515780435
   PubMed Web of Science ®Google Scholar
• VilsbollTKrarupTDeaconCMadsbadSHolstJReduced postprandial concentrations of intact biologically active glucagons-like peptide 1 in type 2 diabetic patientsDiabetes20015060961311246881
   PubMed Web of Science ®Google Scholar
• LangleyAKSuffolettaTJJenningsHRDipeptidyl peptidase IV inhibitors and the incretin system in type 2 diabetes mellitusPharmacotherapy20072781163118017655515
   PubMed Web of Science ®Google Scholar
• KarasikAAschnerPKatzeffHDaviesMSteinPSitagliptin, a dpp-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trialsCurr Med Res Opin200824248949618182122
   PubMed Web of Science ®Google Scholar
• BrazgRXuLManCEffect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycemic control and β-cell function in patients with type 2 diabetesDiabetes Obes Metab2007918619317300594
   PubMed Web of Science ®Google Scholar
• GoldsteinFeinglosMLuncefordJEffect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetesDiabetes Care20073081979198717485570
   PubMed Web of Science ®Google Scholar
• CharbonnelKarasikALiuJEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin aloneDiabetes Care200629122638264317130197
   PubMed Web of Science ®Google Scholar
• KarasikAWuMWilliams-HermanDSitagliptin added to ongoing metformin therapy provides sustained glycemic control over 54 weeks, with a low incidence of hypoglycemia and with weight loss (abstract 0523-P)Diabetes Care2005281083109115855571
   PubMed Web of Science ®Google Scholar
• NauckMMeiningerGShengDEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, noninferiority trialDiabetes Obes Metab2007919420517300595
   PubMed Web of Science ®Google Scholar
• HermansenKKipnesMLuoEEfficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metforminDiabetes Obes Metab2007973374517593236
   PubMed Web of Science ®Google Scholar
• RosenstockJBrazgRAndryukPEfficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group studyClin Ther200628101556156817157112
   PubMed Web of Science ®Google Scholar
• VanDeKoppelSChoeHMSweetBVManaged care perspective on three new agents for type 2 diabetesJ Manag Care Pharm200814436338018500914
   PubMed Web of Science ®Google Scholar
• HermanGABergmanAYiBKipnesMfor the sitagliptin study 012 groupTolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetesCurr Med Res Opin200622101939194717022853
   PubMed Web of Science ®Google Scholar
• FlorentinMLiberopoulosENMikhailidisDPElisafMSSitagliptin in clinical practice: a new approach in the treatment of type 2 diabetesExpert Opin Pharmacother20089101705172018570604
   PubMed Web of Science ®Google Scholar
• Janumet package insertWhitehouse Station, NJMerck and company2008 http://www.merck.com/product/usa/pi_circulars/j/janumet/janumet_pi.pdf
   Google Scholar
• Glucophage (metformin), package insertPrinceton, NJBristol-Myers Squibb Company2008 http://packageinserts.bms.com/pi/pi_glucophage.pdf
   Google Scholar
• Januvia package insertWhitehouse Station, NJMerck and company2008 http://www.merck.com/product/usa/pi_circulars/j/januvia/januvia_pi.pdf
   Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for Study of DiabetesDiabetes Care20062981963197116873813
   PubMed Web of Science ®Google Scholar
• KrentzAJBaileyCJOral antidiabetic agents current role in type 2 diabetesDrugs200565338541115669880
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBMedical management of hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for Study of DiabetesDiabetes Care20083112111
   Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycemia in Type 2 Diabetes: A consensus algorithm for the initiation and adjustment of therapy. Update regarding thiazolidinediones: a consensus statement from the American Diabetes Association and the European Association for Study of DiabetesDiabetes Care200831117317518165348
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med200735611517202448
   PubMed Web of Science ®Google Scholar
• SinghSLokeYKFurbergCDLong-term risk of cardiovascular events with rosiglitazone: a meta-analysisJAMA2007298101189119517848653
   PubMed Web of Science ®Google Scholar